The Cancer Diagnostics stage will demonstrate how we can utilise the advances in molecular profiling of cancers, and their complexity, to improve the way you diagnose and treat cancer in the clinical setting, with a focus on improving precision medicine for better patient outcomes.
11:30
-
Cancer Diagnostics Stage30 minsUsing a multi-modal approach to liquid biopsy combining genomics, epigenomics and fragmentomic assays applied to several precision medicine applications. Demonstrating the utility of this analysis for ...
)
12:00
-
Cancer Diagnostics Stage30 minsCell-free DNA (cfDNA) methylation profiling identifies prostate cancer-specific genes and transcription programs from metastatic castration-resistant prostate cancer (mCRPC) patients. Loss of 5-methyl ...
12:30
-
Cancer Diagnostics Stage30 mins
)
13:00
-
Cancer Diagnostics Stage70 mins
14:10
-
Cancer Diagnostics Stage30 minsThis talk will demonstrate how methylation biomarkers can be detected from liquid biopsy tests to support early cancer detection and monitoring. Using methylation based liquid biopsies as a tumour n ...
)
14:40
-
Cancer Diagnostics Stage30 minsLiquid biopsies could improve cancer detection and monitoring but require higher sensitivity First, I will describe a tumor-informed, whole-genome, mutation enrichment sequencing test for minimal resi ...
)
15:10
-
Cancer Diagnostics Stage30 minsCirculating tumor cells (CTCs) shed from the primary and metastatic tumor deposits provide unparalleled opportunities for cancer diagnostics, disease monitoring, and treatment selection. Despite their ...
)
15:40
-
Cancer Diagnostics Stage30 mins
16:10
-
Cancer Diagnostics Stage30 minsIntroducing novel transformers for learning and simulating cancer evolution Demonstrating how LLMs are accurate and flexible cell type annotators Modeling cancer drug response using pre-trained sing ...
)
16:40
-
Cancer Diagnostics Stage30 minsIntegrating Data to Uncover Molecular Mechanisms of Cancer Development and Genotype-Phenotype Insights Pediatric leukemias are highly heterogeneous, even within well-defined genomic subtypes. By mov ...
)
17:10
-
Cancer Diagnostics Stage30 minsBreast cancer now undergoes routine molecular phenotyping leading to improved prognostication and use of targeted therapies Liquid biopsies are increasing being used for research and clinical care. Da ...
)
11:30
-
Cancer Diagnostics Stage30 minsEstablishing liquid biopsies for early cancer detection and screening. Where can they most provide value. MCEDs currently available? How are liquid biopsies optimising cancer diagnosis. How can we acc ...
)
)
)
12:00
-
Cancer Diagnostics Stage30 minsIntroduction to an innovative approach for developing reference standards that closely resemble clinical samples. Insights from multi-year benchmarking efforts across different MRD detection methods. ...
)
12:30
-
Cancer Diagnostics Stage30 minsNegative selection-based microfluidic technologies enable high resolution multi-omic profiling of rare CTCs from patient blood Single cell RNA-seq of CTCs from patients with prostate cancer can be use ...
)
13:00
-
Cancer Diagnostics Stage50 mins
13:50
-
Cancer Diagnostics Stage30 minsMass-spectrometry-based proteomic analysis on extracellular vesicles to uncover new biomarkers to support the diagnosis and management of genitourinary cancers. Using these EV-derived biomarkers to ...
)
14:20
-
Cancer Diagnostics Stage30 minsThe emerging promise of T cell receptor therapies (TCR-Ts) for cancer treatment Navigating challenges of predictive biomarkers for TCR-T cell therapy Key considerations for the successful development ...
)
14:50
-
Cancer Diagnostics Stage30 minsJemperli (dostarlimab), an immunotherapy received FDA's "Breakthrough Therapy Designation" for treating rectal cancer with specific genetic traits (MMRd/MSI-high), showing 100% remission in trial pati ...
)